Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults

计划入组 28 人 · 首次发布于 2005 年 7 月 12 日

Evaluation of Safety and Tolerability of Libella Gene Therapy for Alzheimer's Disease: AAV- hTERT

计划入组 5 人 · 首次发布于 2019 年 10 月 21 日

Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT

计划入组 5 人 · 首次发布于 2019 年 10 月 1 日

LGT-209

AAV-hTERT

LGT (TP21)/DEN4(NIAID)

CRESTONE, INC.

United States

LEWISHAM AND GREENWICH NHS TRUST

United Kingdom

Corestone Corporation

United States

Vaxxas Secures A$90 Million to Advance Needle-Free Vaccine Delivery Technology Toward Market

Crestone's CRS3123 Shows Promise in Phase 2 Trial for C. difficile Infection

Crestone's CRS3123 Shows Superior Efficacy in Phase 2 Trial for C. difficile Infections